GLPwatch
Byetta vs Zepbound
Drug comparison
Last updated 2026-05-28 15:46 UTCByetta (exenatide by AstraZeneca) is a once-daily injection for type 2 diabetes, while Zepbound (tirzepatide by Eli Lilly) is a once-weekly injection approved for obesity and obstructive sleep apnea. Both are given under the skin, but they use different active ingredients and treat different conditions.
AI summary of the sources below.
| Byetta | Zepbound | |
|---|---|---|
| Active ingredient | exenatide | tirzepatide |
| Manufacturer | astrazeneca | eli-lilly |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes | obesity, obstructive sleep apnea |
| Label updated | 2025-09-02 | 2026-04-22 |